期刊文献+

雷帕霉素药物洗脱支架在急性心肌梗死择期介入治疗中应用的近远期疗效观察 被引量:1

Evaluation of Short and Long-term Outcomes of Rapamyxin Eluting Stent Using in Delayed Percutaneous Coronaryintervention in Patients of Acute Myocadial Infarction
下载PDF
导出
摘要 目的探讨雷帕霉素药物洗脱支架(Cypher支架)在急性心肌梗死择期介入治疗中应用的安全性及近、远期临床疗效。方法对2003年9月-2004年12月期间55例急性心肌梗死患者于梗死后5-14 d(平均8.6±3.1d)行。PCI,术后随访15~29个月观察有无心绞痛、急性心肌梗死、再次血管重建和死亡事件等。结果55例患者72处靶病变,共置入71个Cypher支架及11个普通金属裸支架,支架置入成功率为100%,术中和住院期间无死亡,住院期间无主要心脏不良事件。随访期间,无死亡病例,无慢性充血性心力衰竭心功能Ⅲ一Ⅳ级(NYHA分级)病例,1例发生急性左心衰,1例发生心绞痛进行了靶病变重建,2例发生急性心肌梗死,主要心脏不良事件发生率7.3%,靶病变重建率1.8%。结论雷帕霉素药物洗脱支架应用于急性心肌梗死择期介入治疗中安全、有效, 具有良好的近远期临床效果。 Objective To investigate the short and long-term clinical outcome of Cypher stent in patients of Acute Myocadial Infarction (AMI) with Delayed Percutaneous Coronaryintervention (PCI). Methods From September 2003 to december 2004,PCI was performed after AMI 5-14 clays in 55 patients. All patientswere followed up for 15 - 29 months for major adverse cardiac event(MACE) such as angina pectoris, myocadial infarction , sudden death and target lession revascularization (TLR). Results 55 patients were treated with 71 Cypher stents and 11 BES. Success rate of stent implantation was 100%. There was no MACE during the procedure and hospitalzation. During the follow-up period one patient occurred acute heart failure, one patient occurred angina pectoris and TLR was performed , AMI occurred in two patients, with a MACE rate of 7.3% ,TLR rate was 1.8%. Conclusion The treatment of rapamyxin eluting stent e using in Delayed Percutaneous Coronaryintervention is safe and effective in patients of AMI.
出处 《中国分子心脏病学杂志》 CAS 2006年第2期73-75,共3页 Molecular Cardiology of China
关键词 药物洗脱支架 急性心肌梗死 经皮冠状动脉介入治疗 Drug Eluting Stent Acute Myocadial Infarction Percutaneous Coronaryintervention
  • 相关文献

参考文献10

  • 1[1]Zahn R,Schiele R,Schneider S,et al.Decreasing hospital mortality between 1994 and 1998 in patients with acute myocardial.infarction treated with primary angioplasty but not in patients treated with intravenous thrombolysis,results from the pooled data of the maximal individual therapy in acute myocardial infarction (MITRA) registry and the myocardial infarction registy.J Am Coll Cardiol,2000,36:2064-2071.
  • 2高润霖.急性心肌梗死诊断和治疗指南[J].中华心血管病杂志,2001,29(12):710-725. 被引量:4922
  • 3[3]Marks AR.Sirolimus for the prevention of in-stent restenosis in a coronary artery.N Engl J Med,2003,349:1307-1309.
  • 4[4]Holmes DR,Leon MB,Moses JW,et al.Analysis of 1 year clinical outcomes in the SIRIUS trial:a randomized trial of a sirolimuse eluting stent versus a standard stent in patients at high risk for coronary restentosis.Circulation,2004,109:634-640.
  • 5[5]Pizzetti G,Belitti G,Margonato A,et al.Coronary recanalization by elective angioplasty prevents ventricular dilation after anterior myocardial infarction.JAm Coll Cardiol,1996,28:837-845.
  • 6[6]DA,Tu JV,Austin PC.Waiting times revascularization modality and outcomes after acute myocardial infarction hospital with and without on-site revascularization facilities in Canada.J Am Coll Cardiol,2003,42:410-419.
  • 7高润霖.药物涂层支架——介入心脏病学的突破性进展[J].中华心血管病杂志,2003,31(3):161-162. 被引量:46
  • 8唐良秋,徐新,马绍椿.应用雷帕霉素药物涂层支架治疗冠脉支架内再狭窄研究[J].中国分子心脏病学杂志,2004,4(1):29-31. 被引量:5
  • 9[9]Moses JW,Leon MB,Popma JJ,et al.Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.N Engl J Med,2003,349:1315-1323.
  • 10[10]Lemos PA,Serruys PW,van Domburg RT,et al.Unrestricted utilization of sirlimus eluting stents compared with conventional bare stent implantation in the "realworld":he Rapamycin in Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) Registry.Circulation,2004,109:190-195.

二级参考文献6

  • 1[1]Schoming A,Kastrati A,Mudra H,et al.Four-year experience with Palamaz-Schatz stenting in coronary angioplasty complicated by dissection with threatened or present vessel closure.Circulation,1994,90:2216-2224.
  • 2[2]Schatz RA,Baim DZ,Leon M,et al.Clinical experience with the Palmtz-Schatz coronary stent:Initial results of multicenter study.Circulation,1991,83:148-161.
  • 3[3]Baim DS,Levine M J,Leon MB,et al.For the U.S.PalmtzSchatz stent investigators:management of restenosis within the Palmatz-Schatz coronary stent (the U.S.multicenter experience).Am J Cardiol,1993,71:364-366.
  • 4[4]Gordon PC,Gibson M,Cohen DJ,et al.Mechanism of restenosis and redilation within coronary stents:Quantitative angiographic assessment.JAm Coll Cardiol,1993,21:1166-1174.
  • 5[5]Satler LF,"Remedies" for in-stent restenosis.Cathet Cardiovas Diagn,1996,337:320-321.
  • 6[6]Mehran R,Mintz GS,Popma JJ,et al.Mechanisms and results of balloon angioplasty for the treatment of in-stent restenosis.Am J Cardiol,1996,78:618-622.

共引文献4970

同被引文献2

  • 1Stone GW,Grines CL, David A,et al. Comparison of Angioplasty with Stenting, with or without Abciximab[J].Acute Myocardial Infarction, 2002,346(12):957-966.
  • 2Alter DA, Tu JV, Austin PC, et al. Waiting times, revascularization modality, and outcomes after acute myocardial infarction at hospitals with and without on-site revascularization facilities in Canada [J]. J Am Coll Cardiol, 2003, 42: 410--419.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部